Immuneering

Immuneering ROE

The Return on Equity (ROE) of Immuneering (IMRX) as of Nov 21, 2026 is -25.64 %. In the previous year, Return on Equity (ROE) was -147.48 % — a change of -82.61% (higher).

ROE

-25.64 %

YoY

-82.61%

Last updated:

In 2025, Immuneering's return on equity (ROE) was -25.64 %, a -82.61% increase from the -147.48 % ROE in the previous year.

The Immuneering ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
118.10 USD
Jan 1, 2020
75.80 USD
Jan 1, 2021
-21.50 USD
Jan 1, 2022
-45.98 USD
Jan 1, 2023
-59.03 USD
Jan 1, 2024
-147.48 USD
Jan 1, 2025
-25.64 USD
The Immuneering ROE history
YEARROEYoY
-25.64 %-82.61%
-147.48 %+149.82%
-59.03 %+28.38%
-45.98 %+113.88%
-21.50 %-128.37%
75.80 %-35.82%
118.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immuneering Stock analysis

What does Immuneering do? Immuneering Corp. develops oncology medicines for cancer patients with universal-RAS therapy, focusing on the lead product candidate IMM-1-104, currently in Phase I/IIa clinical trials for advanced solid tumors with RAS mutations. The company also develops IMM-6-415, which is in IND stage for universal-MAPK activity with twice-daily dosing, alongside Trifecta MEK, RAS modulators, and other small molecule drug discovery programs. Its platform relies on Bioinformatics and 3D Tumor Modeling to enable drug development. The company generates revenue through clinical-stage product development, targeting cancer treatment markets with novel therapies for RAS-mutated tumors. Immuneering Corp. targets oncology markets with its pipeline of therapies, including IMM-1-104 as a once-daily oral monotherapy and IMM-6-415 with accelerated twice-daily dosing. The company’s development approach centers on deep cyclic inhibition of the MAPK pathway for universal-RAS and universal-MAPK activity. Its product candidates are designed for patients with advanced solid tumors harboring RAS mutations, aiming to address unmet medical needs in cancer treatment through innovative small molecule therapies. The company’s business model involves advancing clinical-stage products through development stages, leveraging Bioinformatics and 3D Tumor Modeling to optimize drug discovery. Revenue is derived from the progression of its pipeline, including IMM-1-104 and IMM-6-415, toward potential market approval. Immuneering Corp. focuses on oncology markets with a clinical-stage approach, targeting RAS-mutated cancer patients through its universal-RAS therapy strategy. Immuneering is one of the most popular companies on Eulerpool.

ROE Details

Decoding Immuneering's Return on Equity (ROE)

Immuneering's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Immuneering's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Immuneering's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Immuneering’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Immuneering stock

Return on Equity (ROE) of Immuneering is -25.64 % in 2025.

Return on Equity (ROE) of Immuneering changed from -147.48 % to -25.64 %, representing a -82.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Immuneering since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Immuneering with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Immuneering

All Key Metrics — Immuneering